Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190569 | 1.00 | BACE1 (0.47) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL29695390 | 1.00 | BACE1 (0.47) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL30185798 | 1.00 | BACE1 (0.47) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL31210309 | 1.00 | BACE1 (0.47) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL7054647 | 0.96 | BACE1 (0.45) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL31740710 | 0.96 | BACE1 (0.45) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL13837003 | 0.96 | BACE1 (0.45) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL656294 | 0.96 | BACE1 (0.45) | BACE1FABP5FABP7GPR119JAK2 | |
| SCHEMBL7160206 | 0.89 | BACE1 (0.42) | BACE1IDO1UCHL1 | |
| SCHEMBL12572922 | 0.88 | PDK1 (0.48) | BACE1GPR119NAMPTTERTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2830624-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170369530-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369530-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2013148478-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-7923004-B2 | useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug | XTL BIOPHARMACEUTICALS LTD. (IL) | 2011-04-12 | — | — | US | disclosed |
| US-7923004-B2 | useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug | XTL BIOPHARMACEUTICALS LTD. (IL) | 2011-04-12 | — | — | US | disclosed |
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| US-6800434-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | BACE1 98/4885FABP5 1614/4885FABP7 3485/4885 |
| US-20170369530-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | BACE1 1840/4885FABP5 1197/4885FABP7 1558/4885 |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | HAVCR2, EIF2AK2, MAVS | BACE1 4439/4885FABP5 2809/4885FABP7 4635/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | BACE1 4464/4885FABP5 424/4885FABP7 508/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | BACE1 2555/4885FABP5 501/4885FABP7 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.